EMYRIA LIMITED - Announcements

2.13%

4.6¢

Market Cap $28.12M

Healthcare Biotechnology

Emyria Limited is an Australia-based early-stage drug development company. The Company is... Emyria Limited is an Australia-based early-stage drug development company. The Company is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises MDMA analogue drug development and commercialization of novel serotonin-releasing agents. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like assisted therapy for post-traumatic stress disorder (PTSD) and assisted therapy for treatment-resistant depression. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.More

HELPING PATIENTS ON THEIR JOURNEY TO BETTER HEALTH

Little Green Pharma (ASX:LGP) to benefit as Denmark commits to cannabis pilot program.

Announcements

Filter Results

All Price Sensitive Only

EMD	MDMA Analogue Development Milestone	PRICE SENSITIVE	19/10/21	139.18KB	Share
EMD	Notification of cessation of securities - EMD		18/10/21	23.24KB	Share
EMD	Notification of cessation of securities - EMD		18/10/21	23.34KB	Share
EMD	Notification of cessation of securities - EMD		18/10/21	23.34KB	Share
EMD	Notification regarding unquoted securities - EMD		08/10/21	28.4KB	Share
EMD	Emyria selected to join Palantirs Foundry Builders Program	PRICE SENSITIVE	07/10/21	385.08KB	Share
EMD	EMD Welcomes TGA-Commissioned Report on MDMA and Psilocybin		01/10/21	145.86KB	Share
EMD	Annual Report to shareholders		01/10/21	3.21MB	Share
EMD	Appendix 4G		30/09/21	282.3KB	Share
EMD	Letter to Shareholders - Annual General Meeting		30/09/21	800.56KB	Share
EMD	Notice of Annual General Meeting/Proxy Form		30/09/21	786.59KB	Share
EMD	Lifesciences Webinar Presintation		28/09/21	4.14MB	Share
EMD	Novel MDMA Analogue Screening Program Advanced	PRICE SENSITIVE	22/09/21	145.51KB	Share
EMD	Notification regarding unquoted securities - EMD		22/09/21	27.47KB	Share
EMD	Emyria Expands Psychiatry Advisory for Psychedelics and MDMA	PRICE SENSITIVE	16/09/21	269.06KB	Share
EMD	MDMA-analogues Show Promise for Parkinson's Disease	PRICE SENSITIVE	01/09/21	429.22KB	Share
EMD	Appendix 4E and Full Year Statutory Accounts	PRICE SENSITIVE	31/08/21	1.31MB	Share
EMD	Annual General Meeting		31/08/21	135.89KB	Share
EMD	Emyria Engages Calvert Labs for Preclinical CBD studies	PRICE SENSITIVE	27/08/21	144.91KB	Share
EMD	Emyria Drug Development Overview and Webinar		23/08/21	5.91MB	Share
EMD	Emyria Appoints Expert Neuropharmacologist for MDMA Program	PRICE SENSITIVE	20/08/21	144.04KB	Share
EMD	Emyria Executes Pure CBD Agreement with AltaSciences	PRICE SENSITIVE	13/08/21	150.95KB	Share
EMD	CAN: Cann and Emyria mutually end collaboration	PRICE SENSITIVE	13/08/21	198.02KB	Share
EMD	Emyria and Cann Mutually End Collaboration	PRICE SENSITIVE	13/08/21	146.93KB	Share
EMD	Emyria to Develop Novel Psychedelics Pipeline with UWA	PRICE SENSITIVE	05/08/21	161.32KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	28/07/21	479.05KB	Share
EMD	Principal Investigator Appointed to lead Emyria MDMA trial		29/06/21	174.62KB	Share
EMD	Results of Meeting		18/06/21	148.22KB	Share
EMD	Webinar Presentation		18/06/21	5.34MB	Share
EMD	Investor Webinar Presentation Today		18/06/21	131.68KB	Share
EMD	Emyria Advances EMD-004 Program Towards Registration	PRICE SENSITIVE	15/06/21	147.96KB	Share
EMD	Emyria Investor Webinar		07/06/21	134.61KB	Share
EMD	Emyria Data Validated, Care Model Reduces Opioids	PRICE SENSITIVE	07/06/21	10.36MB	Share
EMD	Details of Company Address		19/05/21	76.19KB	Share
EMD	Notice of General Meeting/Proxy Form		17/05/21	775.72KB	Share
EMD	Emyria Obtains TGA Approval for Medical Grade Monitoring App	PRICE SENSITIVE	12/05/21	439.83KB	Share
EMD	Trading Halt	PRICE SENSITIVE	11/05/21	505.68KB	Share
EMD	Emyria and MMA launch MDMA-assisted therapy program for PTSD	PRICE SENSITIVE	05/05/21	187.44KB	Share
EMD	Appendix 2A and Notice Under Section 708A		28/04/21	360.7KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	28/04/21	861KB	Share
EMD	Proposed issue of Securities - EMD		21/04/21	26.42KB	Share
EMD	Proposed issue of Securities - EMD		21/04/21	29.25KB	Share
EMD	$5m Placement for Drug Registration and Treatment Pipeline	PRICE SENSITIVE	21/04/21	146.91KB	Share
EMD	Trading Halt	PRICE SENSITIVE	19/04/21	369.93KB	Share
EMD	Emyria Drug Registration Model - EMD-003 snapshot		07/04/21	4.8MB	Share
EMD	CAN: Cann and Emyria investor webinar		30/03/21	174.45KB	Share
EMD	Emyria and Cann Group Investor Webinar		30/03/21	158.15KB	Share
EMD	Emyria and Cann Partner to Register CBD Product	PRICE SENSITIVE	29/03/21	175.53KB	Share
EMD	CAN: Cann and Emyria partner to register CBD product		29/03/21	253.19KB	Share
EMD	Appendix 3G		18/03/21	267.14KB	Share
EMD	Emyria CEO in multiple webinars -Wednesday 10th March		08/03/21	132.51KB	Share
EMD	Results of Meeting		05/03/21	132.88KB	Share
EMD	General Meeting Shareholder Update		05/03/21	5.98MB	Share
EMD	Emyria Adds Second Clinical Site in Perth	PRICE SENSITIVE	02/03/21	246.11KB	Share
EMD	Half Yearly Report and Accounts	PRICE SENSITIVE	24/02/21	898.31KB	Share
EMD	Global Pharmaceutical Expert joins Advisory Board		22/02/21	162.16KB	Share
EMD	Proposed issue of Securities - EMD		22/02/21	26.5KB	Share
EMD	Emyria adds second Emerald Clinic in Melbourne	PRICE SENSITIVE	09/02/21	184.75KB	Share
EMD	Emyria wins digital health monitoring grant with UWA	PRICE SENSITIVE	05/02/21	146.04KB	Share
EMD	Letter to Shareholders - General Meeting		03/02/21	312.53KB	Share
EMD	Notice of General Meeting/Proxy Form		03/02/21	803.69KB	Share
EMD	Change in substantial holding SW		03/02/21	210KB	Share
EMD	Emyria adds consultant psychiatrist to Medical Advisory		01/02/21	157.91KB	Share
EMD	FDA Position on RWE to Guide Registration	PRICE SENSITIVE	27/01/21	171.85KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	19/01/21	910.72KB	Share
EMD	Emyria Pursuing Registration of EMD-003 in CY2021	PRICE SENSITIVE	05/01/21	148.83KB	Share
EMD	Appendix 2A and Notice Under Section 708A		22/12/20	317.98KB	Share
EMD	Emyria to Benefit from Final TGA Ruling on CBD Medicines	PRICE SENSITIVE	16/12/20	144.72KB	Share
EMD	Proposed issue of Securities - EMD		16/12/20	26.43KB	Share
EMD	Proposed issue of Securities - EMD		16/12/20	26.42KB	Share
EMD	Proposed issue of Securities - EMD		16/12/20	27.93KB	Share
EMD	Emyria to Accelerate Drug Development with $1.2m Placement	PRICE SENSITIVE	16/12/20	144.58KB	Share
EMD	Trading Halt	PRICE SENSITIVE	14/12/20	507.68KB	Share
EMD	Product Launch Update		08/12/20	3.51MB	Share
EMD	Emyria Sees Strong Interest in IBS Study	PRICE SENSITIVE	03/12/20	246.35KB	Share
EMD	Emyria Launches Drug Development Program Based on RWE	PRICE SENSITIVE	25/11/20	319.37KB	Share
EMD	Emyria Partners with Thought Leaders in Psychedelic Therapy	PRICE SENSITIVE	19/11/20	203.11KB	Share
EMD	Change of Director's Interest Notice SW		16/11/20	264.27KB	Share
EMD	*Change of Director's Interest Notice 4**		13/11/20	354.88KB	Share
EMD	Appendix 3G		13/11/20	272.68KB	Share
EMD	Results of Meeting		13/11/20	127.01KB	Share
EMD	Annual General Meeting Presentation		13/11/20	7.88MB	Share
EMD	Exercise Price of Options		13/11/20	107.31KB	Share
EMD	Emyria Enters Data Deal with Zelira to Support Autism Trial	PRICE SENSITIVE	09/11/20	242.2KB	Share
EMD	Release of Unlisted Options from Escrow		06/11/20	143.95KB	Share
EMD	Emyria receives $954,000 R&D tax incentive refund		02/11/20	192.16KB	Share
EMD	Appendix 4C - Quarterly	PRICE SENSITIVE	29/10/20	358.47KB	Share
EMD	Change of Director's Interest Notice AV		23/10/20	140.52KB	Share
EMD	Webinar on Global Partnership with Sapphire Medical Clinics	PRICE SENSITIVE	21/10/20	188.36KB	Share
EMD	Emyria Enters into Partnership with Sapphire Medical Clinics		21/10/20	254.26KB	Share
EMD	Investor Presentation		14/10/20	11.95MB	Share
EMD	Appendix 4G		09/10/20	285.86KB	Share
EMD	Annual Report to shareholders		09/10/20	2.26MB	Share
EMD	Letter to Shareholders - Annual General Meeting		08/10/20	827.71KB	Share
EMD	Notice of Annual General Meeting/Proxy Form		08/10/20	883.41KB	Share
EMD	Emyria Signs Real-World Data Agreement with Zelira	PRICE SENSITIVE	30/09/20	204.57KB	Share
EMD	Annual General Meeting Date		30/09/20	298.55KB	Share
EMD	ZLD: Signs Real-World Data Agreement for Zenivol with Emyria		30/09/20	229.95KB	Share
EMD	Amended Change in substantial holding SW		24/09/20	139.13KB	Share
EMD	Results of Meeting		18/09/20	146.61KB	Share

EMD MDMA Analogue Development Milestone
19/10/21	PRICE SENSITIVE	139.18KB	Share
EMD Notification of cessation of securities - EMD
18/10/21		23.24KB	Share
EMD Notification of cessation of securities - EMD
18/10/21		23.34KB	Share
EMD Notification of cessation of securities - EMD
18/10/21		23.34KB	Share
EMD Notification regarding unquoted securities - EMD
08/10/21		28.4KB	Share
EMD Emyria selected to join Palantirs Foundry Builders Program
07/10/21	PRICE SENSITIVE	385.08KB	Share
EMD EMD Welcomes TGA-Commissioned Report on MDMA and Psilocybin
01/10/21		145.86KB	Share
EMD Annual Report to shareholders
01/10/21		3.21MB	Share
EMD Appendix 4G
30/09/21		282.3KB	Share
EMD Letter to Shareholders - Annual General Meeting
30/09/21		800.56KB	Share
EMD Notice of Annual General Meeting/Proxy Form
30/09/21		786.59KB	Share
EMD Lifesciences Webinar Presintation
28/09/21		4.14MB	Share
EMD Novel MDMA Analogue Screening Program Advanced
22/09/21	PRICE SENSITIVE	145.51KB	Share
EMD Notification regarding unquoted securities - EMD
22/09/21		27.47KB	Share
EMD Emyria Expands Psychiatry Advisory for Psychedelics and MDMA
16/09/21	PRICE SENSITIVE	269.06KB	Share
EMD MDMA-analogues Show Promise for Parkinson's Disease
01/09/21	PRICE SENSITIVE	429.22KB	Share
EMD Appendix 4E and Full Year Statutory Accounts
31/08/21	PRICE SENSITIVE	1.31MB	Share
EMD Annual General Meeting
31/08/21		135.89KB	Share
EMD Emyria Engages Calvert Labs for Preclinical CBD studies
27/08/21	PRICE SENSITIVE	144.91KB	Share
EMD Emyria Drug Development Overview and Webinar
23/08/21		5.91MB	Share
EMD Emyria Appoints Expert Neuropharmacologist for MDMA Program
20/08/21	PRICE SENSITIVE	144.04KB	Share
EMD Emyria Executes Pure CBD Agreement with AltaSciences
13/08/21	PRICE SENSITIVE	150.95KB	Share
EMD CAN: Cann and Emyria mutually end collaboration
13/08/21	PRICE SENSITIVE	198.02KB	Share
EMD Emyria and Cann Mutually End Collaboration
13/08/21	PRICE SENSITIVE	146.93KB	Share
EMD Emyria to Develop Novel Psychedelics Pipeline with UWA
05/08/21	PRICE SENSITIVE	161.32KB	Share
EMD Appendix 4C - Quarterly
28/07/21	PRICE SENSITIVE	479.05KB	Share
EMD Principal Investigator Appointed to lead Emyria MDMA trial
29/06/21		174.62KB	Share
EMD Results of Meeting
18/06/21		148.22KB	Share
EMD Webinar Presentation
18/06/21		5.34MB	Share
EMD Investor Webinar Presentation Today
18/06/21		131.68KB	Share
EMD Emyria Advances EMD-004 Program Towards Registration
15/06/21	PRICE SENSITIVE	147.96KB	Share
EMD Emyria Investor Webinar
07/06/21		134.61KB	Share
EMD Emyria Data Validated, Care Model Reduces Opioids
07/06/21	PRICE SENSITIVE	10.36MB	Share
EMD Details of Company Address
19/05/21		76.19KB	Share
EMD Notice of General Meeting/Proxy Form
17/05/21		775.72KB	Share
EMD Emyria Obtains TGA Approval for Medical Grade Monitoring App
12/05/21	PRICE SENSITIVE	439.83KB	Share
EMD Trading Halt
11/05/21	PRICE SENSITIVE	505.68KB	Share
EMD Emyria and MMA launch MDMA-assisted therapy program for PTSD
05/05/21	PRICE SENSITIVE	187.44KB	Share
EMD Appendix 2A and Notice Under Section 708A
28/04/21		360.7KB	Share
EMD Appendix 4C - Quarterly
28/04/21	PRICE SENSITIVE	861KB	Share
EMD Proposed issue of Securities - EMD
21/04/21		26.42KB	Share
EMD Proposed issue of Securities - EMD
21/04/21		29.25KB	Share
EMD $5m Placement for Drug Registration and Treatment Pipeline
21/04/21	PRICE SENSITIVE	146.91KB	Share
EMD Trading Halt
19/04/21	PRICE SENSITIVE	369.93KB	Share
EMD Emyria Drug Registration Model - EMD-003 snapshot
07/04/21		4.8MB	Share
EMD CAN: Cann and Emyria investor webinar
30/03/21		174.45KB	Share
EMD Emyria and Cann Group Investor Webinar
30/03/21		158.15KB	Share
EMD Emyria and Cann Partner to Register CBD Product
29/03/21	PRICE SENSITIVE	175.53KB	Share
EMD CAN: Cann and Emyria partner to register CBD product
29/03/21		253.19KB	Share
EMD Appendix 3G
18/03/21		267.14KB	Share
EMD Emyria CEO in multiple webinars -Wednesday 10th March
08/03/21		132.51KB	Share
EMD Results of Meeting
05/03/21		132.88KB	Share
EMD General Meeting Shareholder Update
05/03/21		5.98MB	Share
EMD Emyria Adds Second Clinical Site in Perth
02/03/21	PRICE SENSITIVE	246.11KB	Share
EMD Half Yearly Report and Accounts
24/02/21	PRICE SENSITIVE	898.31KB	Share
EMD Global Pharmaceutical Expert joins Advisory Board
22/02/21		162.16KB	Share
EMD Proposed issue of Securities - EMD
22/02/21		26.5KB	Share
EMD Emyria adds second Emerald Clinic in Melbourne
09/02/21	PRICE SENSITIVE	184.75KB	Share
EMD Emyria wins digital health monitoring grant with UWA
05/02/21	PRICE SENSITIVE	146.04KB	Share
EMD Letter to Shareholders - General Meeting
03/02/21		312.53KB	Share
EMD Notice of General Meeting/Proxy Form
03/02/21		803.69KB	Share
EMD Change in substantial holding SW
03/02/21		210KB	Share
EMD Emyria adds consultant psychiatrist to Medical Advisory
01/02/21		157.91KB	Share
EMD FDA Position on RWE to Guide Registration
27/01/21	PRICE SENSITIVE	171.85KB	Share
EMD Appendix 4C - Quarterly
19/01/21	PRICE SENSITIVE	910.72KB	Share
EMD Emyria Pursuing Registration of EMD-003 in CY2021
05/01/21	PRICE SENSITIVE	148.83KB	Share
EMD Appendix 2A and Notice Under Section 708A
22/12/20		317.98KB	Share
EMD Emyria to Benefit from Final TGA Ruling on CBD Medicines
16/12/20	PRICE SENSITIVE	144.72KB	Share
EMD Proposed issue of Securities - EMD
16/12/20		26.43KB	Share
EMD Proposed issue of Securities - EMD
16/12/20		26.42KB	Share
EMD Proposed issue of Securities - EMD
16/12/20		27.93KB	Share
EMD Emyria to Accelerate Drug Development with $1.2m Placement
16/12/20	PRICE SENSITIVE	144.58KB	Share
EMD Trading Halt
14/12/20	PRICE SENSITIVE	507.68KB	Share
EMD Product Launch Update
08/12/20		3.51MB	Share
EMD Emyria Sees Strong Interest in IBS Study
03/12/20	PRICE SENSITIVE	246.35KB	Share
EMD Emyria Launches Drug Development Program Based on RWE
25/11/20	PRICE SENSITIVE	319.37KB	Share
EMD Emyria Partners with Thought Leaders in Psychedelic Therapy
19/11/20	PRICE SENSITIVE	203.11KB	Share
EMD Change of Director's Interest Notice SW
16/11/20		264.27KB	Share
EMD *Change of Director's Interest Notice 4**
13/11/20		354.88KB	Share
EMD Appendix 3G
13/11/20		272.68KB	Share
EMD Results of Meeting
13/11/20		127.01KB	Share
EMD Annual General Meeting Presentation
13/11/20		7.88MB	Share
EMD Exercise Price of Options
13/11/20		107.31KB	Share
EMD Emyria Enters Data Deal with Zelira to Support Autism Trial
09/11/20	PRICE SENSITIVE	242.2KB	Share
EMD Release of Unlisted Options from Escrow
06/11/20		143.95KB	Share
EMD Emyria receives $954,000 R&D tax incentive refund
02/11/20		192.16KB	Share
EMD Appendix 4C - Quarterly
29/10/20	PRICE SENSITIVE	358.47KB	Share
EMD Change of Director's Interest Notice AV
23/10/20		140.52KB	Share
EMD Webinar on Global Partnership with Sapphire Medical Clinics
21/10/20	PRICE SENSITIVE	188.36KB	Share
EMD Emyria Enters into Partnership with Sapphire Medical Clinics
21/10/20		254.26KB	Share
EMD Investor Presentation
14/10/20		11.95MB	Share
EMD Appendix 4G
09/10/20		285.86KB	Share
EMD Annual Report to shareholders
09/10/20		2.26MB	Share
EMD Letter to Shareholders - Annual General Meeting
08/10/20		827.71KB	Share
EMD Notice of Annual General Meeting/Proxy Form
08/10/20		883.41KB	Share
EMD Emyria Signs Real-World Data Agreement with Zelira
30/09/20	PRICE SENSITIVE	204.57KB	Share
EMD Annual General Meeting Date
30/09/20		298.55KB	Share
EMD ZLD: Signs Real-World Data Agreement for Zenivol with Emyria
30/09/20		229.95KB	Share
EMD Amended Change in substantial holding SW
24/09/20		139.13KB	Share
EMD Results of Meeting
18/09/20		146.61KB	Share

REFRESH

First 2 3 4

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 4.6¢		Change -0.001(2.13%)		Mkt cap ! $28.12M

Open	High	Low	Value	Volume
4.7¢	4.9¢	4.6¢	$208.3K	4.369M

Buyers (Bids)

No.	Vol.	Price($)
4	244702	4.6¢

Sellers (Offers)

Price($)	Vol.	No.
4.8¢	580000	3

View Market Depth

No.	Vol.	Price($)
3	208695	0.046
3	522000	0.045
3	225907	0.044
2	134883	0.043
2	350084	0.042

Price($)	Vol.	No.
0.048	568000	2
0.049	460000	4
0.050	1384559	9
0.051	100000	2
0.052	64230	2

Last trade - 16.10pm 08/08/2025 (20 minute delay)

EMD (ASX) Chart

EMYRIA LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories